Innoviva, Inc. (NASDAQ:INVA) Stake Increased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. raised its stake in shares of Innoviva, Inc. (NASDAQ:INVA) by 44.1% during the third quarter, HoldingsChannel reports. The fund owned 136,722 shares of the biotechnology company’s stock after acquiring an additional 41,827 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Innoviva were worth $2,640,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. US Bancorp DE grew its position in shares of Innoviva by 24.5% in the 3rd quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 566 shares in the last quarter. First Trust Direct Indexing L.P. lifted its stake in Innoviva by 18.4% during the third quarter. First Trust Direct Indexing L.P. now owns 12,013 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 1,868 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Innoviva by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,033 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 4,698 shares during the period. Semanteon Capital Management LP increased its stake in Innoviva by 88.5% during the third quarter. Semanteon Capital Management LP now owns 47,247 shares of the biotechnology company’s stock valued at $912,000 after purchasing an additional 22,181 shares during the last quarter. Finally, Creative Planning raised its holdings in shares of Innoviva by 21.1% during the third quarter. Creative Planning now owns 26,780 shares of the biotechnology company’s stock worth $517,000 after purchasing an additional 4,669 shares during the period. 99.12% of the stock is owned by institutional investors and hedge funds.

Innoviva Trading Up 0.5 %

Shares of INVA stock opened at $19.36 on Tuesday. The firm has a market capitalization of $1.21 billion, a PE ratio of 11.73 and a beta of 0.57. The company has a debt-to-equity ratio of 0.67, a quick ratio of 11.40 and a current ratio of 12.70. Innoviva, Inc. has a 1 year low of $13.31 and a 1 year high of $20.37. The stock has a fifty day moving average of $19.55 and a two-hundred day moving average of $17.66.

Analyst Ratings Changes

Several research firms have recently commented on INVA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Innoviva in a report on Tuesday, July 30th. StockNews.com downgraded Innoviva from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 6th.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.